// App-Quantinova.ai

800 : A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.

Researchers

Presenter

  • Lipika Goyal

Principal Investigators

  • Matthew B. Yurgelun

  • Michelle Knowles

  • Eileen Regan

  • Amy Gisondi

  • Susan Sheehan

  • Hui Zheng

  • Andrew X. Zhu

  • Thomas Adam Abrams

  • Eunice Lee Kwak

  • James M. Cleary

Medical Centers

  • Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

  • Massachusetts General Hospital Cancer Center, Boston, MAMGH Cancer Center, Boston, MAMassachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01954745

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved